

Jasmohan Bajaj

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9540416/publications.pdf>

Version: 2024-02-01

345
papers

24,844
citations

6250

80
h-index

8852

145
g-index

352
all docs

352
docs citations

352
times ranked

16589
citing authors

#	ARTICLE	IF	CITATIONS
1	Hepatic encephalopathy in chronic liver disease: 2014 Practice Guideline by the American Association for the Study Of Liver Diseases and the European Association for the Study of the Liver. <i>Hepatology</i> , 2014, 60, 715-735.	3.6	1,498
2	Bile acids and the gut microbiome. <i>Current Opinion in Gastroenterology</i> , 2014, 30, 332-338.	1.0	990
3	Altered profile of human gut microbiome is associated with cirrhosis and its complications. <i>Journal of Hepatology</i> , 2014, 60, 940-947.	1.8	873
4	Modulation of the fecal bile acid profile by gut microbiota in cirrhosis. <i>Journal of Hepatology</i> , 2013, 58, 949-955.	1.8	613
5	Impact of <i>Clostridium difficile</i> on Inflammatory Bowel Disease. <i>Clinical Gastroenterology and Hepatology</i> , 2007, 5, 345-351.	2.4	515
6	Colonic mucosal microbiome differs from stool microbiome in cirrhosis and hepatic encephalopathy and is linked to cognition and inflammation. <i>American Journal of Physiology - Renal Physiology</i> , 2012, 303, G675-G685.	1.6	462
7	Survival in infection-related acute-on-chronic liver failure is defined by extrahepatic organ failures. <i>Hepatology</i> , 2014, 60, 250-256.	3.6	456
8	Fecal microbiota transplant from a rational stool donor improves hepatic encephalopathy: A randomized clinical trial. <i>Hepatology</i> , 2017, 66, 1727-1738.	3.6	454
9	Linkage of gut microbiome with cognition in hepatic encephalopathy. <i>American Journal of Physiology - Renal Physiology</i> , 2012, 302, G168-G175.	1.6	448
10	Alcohol, liver disease and the gut microbiota. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2019, 16, 235-246.	8.2	421
11	Second infections independently increase mortality in hospitalized patients With cirrhosis: the north american consortium for the study of end-stage liver disease (NACSELD) experience. <i>Hepatology</i> , 2012, 56, 2328-2335.	3.6	357
12	Modulation of the Metabiome by Rifaximin in Patients with Cirrhosis and Minimal Hepatic Encephalopathy. <i>PLoS ONE</i> , 2013, 8, e60042.	1.1	340
13	Targeting the gut-liver axis in liver disease. <i>Journal of Hepatology</i> , 2017, 67, 1084-1103.	1.8	311
14	Spectrum of neurocognitive impairment in cirrhosis: Implications for the assessment of hepatic encephalopathy. <i>Hepatology</i> , 2009, 50, 2014-2021.	3.6	296
15	The Multi-Dimensional Burden of Cirrhosis and Hepatic Encephalopathy on Patients and Caregivers. <i>American Journal of Gastroenterology</i> , 2011, 106, 1646-1653.	0.2	288
16	Review article: the design of clinical trials in hepatic encephalopathy - an International Society for Hepatic Encephalopathy and Nitrogen Metabolism (ISHEN) consensus statement. <i>Alimentary Pharmacology and Therapeutics</i> , 2011, 33, 739-747.	1.9	285
17	Persistence of Cognitive Impairment After Resolution of Overt Hepatic Encephalopathy. <i>Gastroenterology</i> , 2010, 138, 2332-2340.	0.6	276
18	Cirrhosis, bile acids and gut microbiota. <i>Gut Microbes</i> , 2013, 4, 382-387.	4.3	276

#	ARTICLE	IF	CITATIONS
19	Salivary microbiota reflects changes in gut microbiota in cirrhosis with hepatic encephalopathy. <i>Hepatology</i> , 2015, 62, 1260-1271.	3.6	272
20	Minimal hepatic encephalopathy is associated with motor vehicle crashes: The reality beyond the driving test. <i>Hepatology</i> , 2009, 50, 1175-1183.	3.6	270
21	Supplementation of Saturated Long-Chain Fatty Acids Maintains Intestinal Eubiosis and Reduces Ethanol-induced Liver Injury in Mice. <i>Gastroenterology</i> , 2015, 148, 203-214.e16.	0.6	266
22	Toward an Improved Definition of Acute-on-Chronic Liver Failure. <i>Gastroenterology</i> , 2014, 147, 4-10.	0.6	255
23	Management of the critically ill patient with cirrhosis: A multidisciplinary perspective. <i>Journal of Hepatology</i> , 2016, 64, 717-735.	1.8	243
24	Probiotic Yogurt for the Treatment of Minimal Hepatic Encephalopathy. <i>American Journal of Gastroenterology</i> , 2008, 103, 1707-1715.	0.2	235
25	Randomised clinical trial: Lactobacillus GG modulates gut microbiome, metabolome and endotoxemia in patients with cirrhosis. <i>Alimentary Pharmacology and Therapeutics</i> , 2014, 39, 1113-1125.	1.9	234
26	New Consensus Definition of Acute Kidney Injury Accurately Predicts 30-Day Mortality in Patients With Cirrhosis and Infection. <i>Gastroenterology</i> , 2013, 145, 1280-1288.e1.	0.6	221
27	Hepatic encephalopathy: Novel insights into classification, pathophysiology and therapy. <i>Journal of Hepatology</i> , 2020, 73, 1526-1547.	1.8	219
28	Review article: the modern management of hepatic encephalopathy. <i>Alimentary Pharmacology and Therapeutics</i> , 2010, 31, 537-547.	1.9	208
29	Rifaximin Improves Driving Simulator Performance in a Randomized Trial of Patients With Minimal Hepatic Encephalopathy. <i>Gastroenterology</i> , 2011, 140, 478-487.e1.	0.6	207
30	Inhibitory Control Test for the Diagnosis of Minimal Hepatic Encephalopathy. <i>Gastroenterology</i> , 2008, 135, 1591-1600.e1.	0.6	198
31	NACSELD acute-on-chronic liver failure (NACSELD-ACLF) score predicts 30-day survival in hospitalized patients with cirrhosis. <i>Hepatology</i> , 2018, 67, 2367-2374.	3.6	197
32	Fecal Microbial Transplant Capsules Are Safe in Hepatic Encephalopathy: A Phase 1, Randomized, Placebo-Controlled Trial. <i>Hepatology</i> , 2019, 70, 1690-1703.	3.6	196
33	The 3-month readmission rate remains unacceptably high in a large North American cohort of patients with cirrhosis. <i>Hepatology</i> , 2016, 64, 200-208.	3.6	189
34	Distinct signatures of gut microbiome and metabolites associated with significant fibrosis in non-obese NAFLD. <i>Nature Communications</i> , 2020, 11, 4982.	5.8	189
35	Association of Proton Pump Inhibitor Therapy With Spontaneous Bacterial Peritonitis in Cirrhotic Patients With Ascites. <i>American Journal of Gastroenterology</i> , 2009, 104, 1130-1134.	0.2	188
36	The Stroop smartphone application is a short and valid method to screen for minimal hepatic encephalopathy. <i>Hepatology</i> , 2013, 58, 1122-1132.	3.6	180

#	ARTICLE	IF	CITATIONS
37	Comparison of mortality risk in patients with cirrhosis and COVID-19 compared with patients with cirrhosis alone and COVID-19 alone: multicentre matched cohort. <i>Gut</i> , 2021, 70, 531-536.	6.1	178
38	Gastric acid suppression promotes alcoholic liver disease by inducing overgrowth of intestinal <i>Enterococcus</i> . <i>Nature Communications</i> , 2017, 8, 837.	5.8	174
39	Impaired Gut-Liver-Brain Axis in Patients with Cirrhosis. <i>Scientific Reports</i> , 2016, 6, 26800.	1.6	163
40	Microbiota, cirrhosis, and the emerging oral-gut-liver axis. <i>JCI Insight</i> , 2017, 2, .	2.3	163
41	Covert and Overt Hepatic Encephalopathy: Diagnosis and Management. <i>Clinical Gastroenterology and Hepatology</i> , 2015, 13, 2048-2061.	2.4	161
42	Minimal Hepatic Encephalopathy: A Vehicle for Accidents and Traffic Violations. <i>American Journal of Gastroenterology</i> , 2007, 102, 1903-1909.	0.2	158
43	The role of microbiota in hepatic encephalopathy. <i>Gut Microbes</i> , 2014, 5, 397-403.	4.3	157
44	The human gut sterolbiome: bile acid-microbiome endocrine aspects and therapeutics. <i>Acta Pharmaceutica Sinica B</i> , 2015, 5, 99-105.	5.7	153
45	Colonic inflammation and secondary bile acids in alcoholic cirrhosis. <i>American Journal of Physiology - Renal Physiology</i> , 2014, 306, G929-G937.	1.6	151
46	Covert Hepatic Encephalopathy Is Independently Associated With Poor Survival and Increased Risk of Hospitalization. <i>American Journal of Gastroenterology</i> , 2014, 109, 1757-1763.	0.2	150
47	Cholangiocyte-Derived Exosomal Long Noncoding RNA H19 Promotes Hepatic Stellate Cell Activation and Cholestatic Liver Fibrosis. <i>Hepatology</i> , 2019, 70, 1317-1335.	3.6	150
48	Chronic opioid use is associated with altered gut microbiota and predicts readmissions in patients with cirrhosis. <i>Alimentary Pharmacology and Therapeutics</i> , 2017, 45, 319-331.	1.9	149
49	<i>Clostridium difficile</i> Is Associated With Poor Outcomes in Patients With Cirrhosis: A National and Tertiary Center Perspective. <i>American Journal of Gastroenterology</i> , 2010, 105, 106-113.	0.2	146
50	Diagnosis of Minimal Hepatic Encephalopathy Using Stroop EncephalApp: A Multicenter US-Based, Norm-Based Study. <i>American Journal of Gastroenterology</i> , 2016, 111, 78-86.	0.2	138
51	Inhibitory Control Test Is a Simple Method to Diagnose Minimal Hepatic Encephalopathy and Predict Development of Overt Hepatic Encephalopathy. <i>American Journal of Gastroenterology</i> , 2007, 102, 754-760.	0.2	134
52	Navigation skill impairment: Another dimension of the driving difficulties in minimal hepatic encephalopathy. <i>Hepatology</i> , 2008, 47, 596-604.	3.6	134
53	Bile Acid 7Î±-Dehydroxylating Gut Bacteria Secrete Antibiotics that Inhibit <i>Clostridium difficile</i> : Role of Secondary Bile Acids. <i>Cell Chemical Biology</i> , 2019, 26, 27-34.e4.	2.5	134
54	Minimal hepatic encephalopathy matters in daily life. <i>World Journal of Gastroenterology</i> , 2008, 14, 3609.	1.4	132

#	ARTICLE	IF	CITATIONS
55	Systems biology analysis of omeprazole therapy in cirrhosis demonstrates significant shifts in gut microbiota composition and function. <i>American Journal of Physiology - Renal Physiology</i> , 2014, 307, G951-G957.	1.6	125
56	A Randomized Clinical Trial of Fecal Microbiota Transplant for Alcohol Use Disorder. <i>Hepatology</i> , 2021, 73, 1688-1700.	3.6	124
57	Microbiota changes and intestinal microbiota transplantation in liver diseases and cirrhosis. <i>Journal of Hepatology</i> , 2020, 72, 1003-1027.	1.8	123
58	Validation of EncephalApp, Smartphone-Based Stroop Test, for the Diagnosis of Covert Hepatic Encephalopathy. <i>Clinical Gastroenterology and Hepatology</i> , 2015, 13, 1828-1835.e1.	2.4	122
59	Long-term Outcomes of Fecal Microbiota Transplantation in Patients With Cirrhosis. <i>Gastroenterology</i> , 2019, 156, 1921-1923.e3.	0.6	117
60	Cholangiocyte-derived exosomal long noncoding RNA H19 promotes cholestatic liver injury in mouse and humans. <i>Hepatology</i> , 2018, 68, 599-615.	3.6	115
61	Fungal dysbiosis in cirrhosis. <i>Gut</i> , 2018, 67, 1146-1154.	6.1	112
62	Diagnosis and treatment of minimal hepatic encephalopathy to prevent motor vehicle accidents: A cost-effectiveness analysis. <i>Hepatology</i> , 2012, 55, 1164-1171.	3.6	109
63	A simple and accurate HPLC method for fecal bile acid profile in healthy and cirrhotic subjects: validation by GC-MS and LC-MS. <i>Journal of Lipid Research</i> , 2014, 55, 978-990.	2.0	108
64	Antibiotic-Associated Disruption of Microbiota Composition and Function in Cirrhosis Is Restored by Fecal Transplant. <i>Hepatology</i> , 2018, 68, 1549-1558.	3.6	108
65	The microbiota in cirrhosis and its role in hepatic decompensation. <i>Journal of Hepatology</i> , 2021, 75, S67-S81.	1.8	107
66	Mucosa-associated invariant T cells link intestinal immunity with antibacterial immune defects in alcoholic liver disease. <i>Gut</i> , 2018, 67, 918-930.	6.1	106
67	Long-term Use of Antibiotics and Proton Pump Inhibitors Predict Development of Infections in Patients With Cirrhosis. <i>Clinical Gastroenterology and Hepatology</i> , 2015, 13, 753-759.e2.	2.4	105
68	Hepatic Encephalopathy Is Associated With Mortality in Patients With Cirrhosis Independent of Other Extrahepatic Organ Failures. <i>Clinical Gastroenterology and Hepatology</i> , 2017, 15, 565-574.e4.	2.4	105
69	Altered Microbiome in Patients With Cirrhosis and Complications. <i>Clinical Gastroenterology and Hepatology</i> , 2019, 17, 307-321.	2.4	105
70	Predictors of the recurrence of hepatic encephalopathy in lactulose-treated patients. <i>Alimentary Pharmacology and Therapeutics</i> , 2010, 31, 1012-1017.	1.9	99
71	Liver transplant modulates gut microbial dysbiosis and cognitive function in cirrhosis. <i>Liver Transplantation</i> , 2017, 23, 907-914.	1.3	99
72	Review article: potential mechanisms of action of rifaximin in the management of hepatic encephalopathy and other complications of cirrhosis. <i>Alimentary Pharmacology and Therapeutics</i> , 2016, 43, 11-26.	1.9	98

#	ARTICLE	IF	CITATIONS
73	Proton Pump Inhibitor Initiation and Withdrawal affects Gut Microbiota and Readmission Risk in Cirrhosis. <i>American Journal of Gastroenterology</i> , 2018, 113, 1177-1186.	0.2	98
74	North American Practice-Based Recommendations for Transjugular Intrahepatic Portosystemic Shunts in Portal Hypertension. <i>Clinical Gastroenterology and Hepatology</i> , 2022, 20, 1636-1662.e36.	2.4	95
75	Proton pump inhibitors are associated with a high rate of serious infections in veterans with decompensated cirrhosis. <i>Alimentary Pharmacology and Therapeutics</i> , 2012, 36, 866-874.	1.9	94
76	Diet affects gut microbiota and modulates hospitalization risk differentially in an international cirrhosis cohort. <i>Hepatology</i> , 2018, 68, 234-247.	3.6	92
77	Antibiotics for the treatment of hepatic encephalopathy. <i>Metabolic Brain Disease</i> , 2013, 28, 307-312.	1.4	90
78	Gut Microbiota, Cirrhosis, and Alcohol Regulate Bile Acid Metabolism in the Gut. <i>Digestive Diseases</i> , 2015, 33, 338-345.	0.8	90
79	Decompensated cirrhosis and microbiome interpretation. <i>Nature</i> , 2015, 525, E1-E2.	13.7	90
80	Acute-on-Chronic Liver Failure Clinical Guidelines. <i>American Journal of Gastroenterology</i> , 2022, 117, 225-252.	0.2	90
81	Association Between Intestinal Microbiota Collected at Hospital Admission and Outcomes of Patients With Cirrhosis. <i>Clinical Gastroenterology and Hepatology</i> , 2019, 17, 756-765.e3.	2.4	89
82	A longitudinal systems biology analysis of lactulose withdrawal in hepatic encephalopathy. <i>Metabolic Brain Disease</i> , 2012, 27, 205-215.	1.4	88
83	Prediction of Fungal Infection Development and Their Impact on Survival Using the NACSELD Cohort. <i>American Journal of Gastroenterology</i> , 2018, 113, 556-563.	0.2	87
84	Important Unresolved Questions in the Management of Hepatic Encephalopathy: An ISHEN Consensus. <i>American Journal of Gastroenterology</i> , 2020, 115, 989-1002.	0.2	87
85	Continued Alcohol Misuse in Human Cirrhosis is Associated with an Impaired Gut-Liver Axis. <i>Alcoholism: Clinical and Experimental Research</i> , 2017, 41, 1857-1865.	1.4	86
86	Acute-on-Chronic Liver Failure: Getting Ready for Prime Time?. <i>Hepatology</i> , 2018, 68, 1621-1632.	3.6	86
87	The Evolving Challenge of Infections in Cirrhosis. <i>New England Journal of Medicine</i> , 2021, 384, 2317-2330.	13.9	85
88	Gut microbiota drive the development of neuroinflammatory response in cirrhosis in mice. <i>Hepatology</i> , 2016, 64, 1232-1248.	3.6	83
89	Bacterial infections in end-stage liver disease: current challenges and future directions. <i>Gut</i> , 2012, 61, 1219-1225.	6.1	81
90	Covert Hepatic Encephalopathy: Not as Minimal as You Might Think. <i>Clinical Gastroenterology and Hepatology</i> , 2012, 10, 1208-1219.	2.4	78

#	ARTICLE	IF	CITATIONS
91	Gut microbiome and liver disease. <i>Translational Research</i> , 2017, 179, 49-59.	2.2	78
92	Role of gut microbiota in liver disease. <i>American Journal of Physiology - Renal Physiology</i> , 2020, 318, G84-G98.	1.6	78
93	Neuroinflammation in Murine Cirrhosis Is Dependent on the Gut Microbiome and Is Attenuated by Fecal Transplant. <i>Hepatology</i> , 2020, 71, 611-626.	3.6	76
94	Increased Rates of Early Adverse Reaction to Azathioprine in Patients with Crohn's Disease Compared to Autoimmune Hepatitis: A Tertiary Referral Center Experience. <i>American Journal of Gastroenterology</i> , 2005, 100, 1121-1125.	0.2	75
95	Rifaximin Exerts Beneficial Effects Independent of its Ability to Alter Microbiota Composition. <i>Clinical and Translational Gastroenterology</i> , 2016, 7, e187.	1.3	75
96	Gut Microbiota Alterations can predict Hospitalizations in Cirrhosis Independent of Diabetes Mellitus. <i>Scientific Reports</i> , 2015, 5, 18559.	1.6	74
97	A Karnofsky performance status-based score predicts death after hospital discharge in patients with cirrhosis. <i>Hepatology</i> , 2017, 65, 217-224.	3.6	74
98	PROMIS computerised adaptive tests are dynamic instruments to measure health-related quality of life in patients with cirrhosis. <i>Alimentary Pharmacology and Therapeutics</i> , 2011, 34, 1123-1132.	1.9	73
99	Gut Microbiota and Complications of Liver Disease. <i>Gastroenterology Clinics of North America</i> , 2017, 46, 155-169.	1.0	73
100	Enhancement of functional connectivity, working memory and inhibitory control on multi-modal brain MR imaging with Rifaximin in Cirrhosis: Implications for the gut-liver-brain axis. <i>Metabolic Brain Disease</i> , 2014, 29, 1017-1025.	1.4	70
101	Correction of hyponatraemia improves cognition, quality of life, and brain oedema in cirrhosis. <i>Journal of Hepatology</i> , 2015, 62, 75-82.	1.8	67
102	Acute Kidney Injury in Cirrhosis: Baseline Serum Creatinine Predicts Patient Outcomes. <i>American Journal of Gastroenterology</i> , 2017, 112, 1103-1110.	0.2	67
103	The Use of Rifaximin in Patients With Cirrhosis. <i>Hepatology</i> , 2021, 74, 1660-1673.	3.6	67
104	Serum Levels of Metabolites Produced by Intestinal Microbes and Lipid Moieties Independently Associated With Acute-on-Chronic Liver Failure and Death in Patients With Cirrhosis. <i>Gastroenterology</i> , 2020, 159, 1715-1730.e12.	0.6	65
105	Alterations in gut microbial function following liver transplant. <i>Liver Transplantation</i> , 2018, 24, 752-761.	1.3	63
106	Patients With Minimal Hepatic Encephalopathy Have Poor Insight Into Their Driving Skills. <i>Clinical Gastroenterology and Hepatology</i> , 2008, 6, 1135-1139.	2.4	62
107	Periodontal therapy favorably modulates the oral-gut-hepatic axis in cirrhosis. <i>American Journal of Physiology - Renal Physiology</i> , 2018, 315, G824-G837.	1.6	61
108	Effects of N-acetylcysteine on cytokines in non-acetaminophen acute liver failure: potential mechanism of improvement in transplant-free survival. <i>Liver International</i> , 2013, 33, 1324-1331.	1.9	59

#	ARTICLE	IF	CITATIONS
109	Diagnosis of Covert Hepatic Encephalopathy Without Specialized Tests. <i>Clinical Gastroenterology and Hepatology</i> , 2014, 12, 1384-1389.e2.	2.4	59
110	High risk of delisting or death in liver transplant candidates following infections: Results from the North American consortium for the study of end-stage liver disease. <i>Liver Transplantation</i> , 2015, 21, 881-888.	1.3	59
111	C/EBP homologous protein-induced loss of intestinal epithelial stemness contributes to bile duct ligation-induced cholestatic liver injury in mice. <i>Hepatology</i> , 2018, 67, 1441-1457.	3.6	57
112	Lactulose improves cognition, quality of life, and gut microbiota in minimal hepatic encephalopathy: A multicenter, randomized controlled trial. <i>Journal of Digestive Diseases</i> , 2019, 20, 547-556.	0.7	57
113	The Effect of Fatigue on Driving Skills in Patients With Hepatic Encephalopathy. <i>American Journal of Gastroenterology</i> , 2009, 104, 898-905.	0.2	56
114	Management options for minimal hepatic encephalopathy. <i>Expert Review of Gastroenterology and Hepatology</i> , 2008, 2, 785-790.	1.4	55
115	Cognitive Dysfunction Is Associated With Poor Socioeconomic Status in Patients With Cirrhosis: An International Multicenter Study. <i>Clinical Gastroenterology and Hepatology</i> , 2013, 11, 1511-1516.	2.4	55
116	Impact of Chronic Kidney Disease on Outcomes in Cirrhosis. <i>Liver Transplantation</i> , 2019, 25, 870-880.	1.3	55
117	Elderly patients have an altered gut-brain axis regardless of the presence of cirrhosis. <i>Scientific Reports</i> , 2016, 6, 38481.	1.6	54
118	HCV eradication does not impact gut dysbiosis or systemic inflammation in cirrhotic patients. <i>Alimentary Pharmacology and Therapeutics</i> , 2016, 44, 638-643.	1.9	53
119	Terlipressin Improves Renal Function and Reverses Hepatorenal Syndrome in Patients With Systemic Inflammatory Response Syndrome. <i>Clinical Gastroenterology and Hepatology</i> , 2017, 15, 266-272.e1.	2.4	53
120	Outcomes After Listing for Liver Transplant in Patients With Acute-on-Chronic Liver Failure: The Multicenter North American Consortium for the Study of End-stage Liver Disease Experience. <i>Liver Transplantation</i> , 2019, 25, 571-579.	1.3	53
121	Interaction of bacterial metagenome and virome in patients with cirrhosis and hepatic encephalopathy. <i>Gut</i> , 2021, 70, 1162-1173.	6.1	53
122	The patient buddy app can potentially prevent hepatic encephalopathy-related readmissions. <i>Liver International</i> , 2017, 37, 1843-1851.	1.9	52
123	Mindfulness-Based Stress Reduction Therapy Improves Patient and Caregiver-Reported Outcomes in Cirrhosis. <i>Clinical and Translational Gastroenterology</i> , 2017, 8, e108.	1.3	51
124	Changes in the Microbiome in Cirrhosis and Relationship to Complications: Hepatic Encephalopathy, Spontaneous Bacterial Peritonitis, and Sepsis. <i>Seminars in Liver Disease</i> , 2016, 36, 327-330.	1.8	50
125	Impact of Hepatic Encephalopathy in Cirrhosis on Quality-of-Life Issues. <i>Drugs</i> , 2019, 79, 11-16.	4.9	50
126	Specific Gut and Salivary Microbiota Patterns Are Linked With Different Cognitive Testing Strategies in Minimal Hepatic Encephalopathy. <i>American Journal of Gastroenterology</i> , 2019, 114, 1080-1090.	0.2	50

#	ARTICLE	IF	CITATIONS
127	Coagulation profile and platelet function in patients with extrahepatic portal vein obstruction and non-cirrhotic portal fibrosis. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2001, 16, 641-646.	1.4	49
128	Influence of Sleep Stages on Esophago-Upper Esophageal Sphincter Contractile Reflex and Secondary Esophageal Peristalsis. <i>Gastroenterology</i> , 2006, 130, 17-25.	0.6	49
129	Chronic Liver Diseases and the Microbiome—Translating Our Knowledge of Gut Microbiota to Management of Chronic Liver Disease. <i>Gastroenterology</i> , 2021, 160, 556-572.	0.6	49
130	Microbial functional change is linked with clinical outcomes after capsular fecal transplant in cirrhosis. <i>JCI Insight</i> , 2019, 4, .	2.3	49
131	Differential impact of hyponatremia and hepatic encephalopathy on health-related quality of life and brain metabolite abnormalities in cirrhosis. <i>Journal of Hepatology</i> , 2013, 59, 467-473.	1.8	48
132	Beta-blockers in hospitalised patients with cirrhosis and ascites: mortality and factors determining discontinuation and reinitiation. <i>Alimentary Pharmacology and Therapeutics</i> , 2018, 47, 78-85.	1.9	47
133	Neutrophil-to-Lymphocyte Ratio Associates Independently With Mortality in Hospitalized Patients With Cirrhosis. <i>Clinical Gastroenterology and Hepatology</i> , 2018, 16, 1786-1791.e1.	2.4	47
134	Posttraumatic stress disorder is associated with altered gut microbiota that modulates cognitive performance in veterans with cirrhosis. <i>American Journal of Physiology - Renal Physiology</i> , 2019, 317, G661-G669.	1.6	47
135	The Intestinal Microbiota and Liver Disease. <i>American Journal of Gastroenterology Supplements (Print)</i> , 2012, 1, 9-14.	0.7	46
136	Minimal Hepatic Encephalopathy and Mild Cognitive Impairment Worsen Quality of Life in Elderly Patients With Cirrhosis. <i>Clinical Gastroenterology and Hepatology</i> , 2020, 18, 3008-3016.e2.	2.4	46
137	The etiology of cirrhosis is a strong determinant of brain reserve: A multimodal magnetic resonance imaging study. <i>Liver Transplantation</i> , 2015, 21, 1123-1132.	1.3	45
138	Current Management of Hepatic Encephalopathy. <i>American Journal of Gastroenterology</i> , 2018, 113, 1600-1612.	0.2	45
139	Statin use and infections in Veterans with cirrhosis. <i>Alimentary Pharmacology and Therapeutics</i> , 2013, 38, 611-618.	1.9	44
140	Prolonged remission from hepatic encephalopathy with rifaximin: results of a placebo crossover analysis. <i>Alimentary Pharmacology and Therapeutics</i> , 2015, 41, 39-45.	1.9	44
141	The Impact of Albumin Use on Resolution of Hyponatremia in Hospitalized Patients With Cirrhosis. <i>American Journal of Gastroenterology</i> , 2018, 113, 1339.	0.2	44
142	Drug therapy: Rifaximin. <i>Hepatology</i> , 2010, 52, 1484-1488.	3.6	43
143	Model for End-Stage Liver Disease—Lactate and Prediction of Inpatient Mortality in Patients With Chronic Liver Disease. <i>Hepatology</i> , 2020, 72, 1747-1757.	3.6	42
144	Prospective, Randomized Trial Comparing Effect of Oral Versus Intravenous Pantoprazole on Rebleeding After Nonvariceal Upper Gastrointestinal Bleeding: A Pilot Study. <i>Digestive Diseases and Sciences</i> , 2007, 52, 2190-2194.	1.1	41

#	ARTICLE	IF	CITATIONS
145	Advances in the Evaluation and Management of Minimal Hepatic Encephalopathy. Current Gastroenterology Reports, 2011, 13, 26-33.	1.1	41
146	Nosocomial Infections Are Frequent and Negatively Impact Outcomes in Hospitalized Patients With Cirrhosis. American Journal of Gastroenterology, 2019, 114, 1091-1100.	0.2	41
147	Fecal Microbiota Transplant in Cirrhosis Reduces Gut Microbial Antibiotic Resistance Genes: Analysis of Two Trials. Hepatology Communications, 2021, 5, 258-271.	2.0	41
148	Targets to improve quality of care for patients with hepatic encephalopathy: data from a multicentre cohort. Alimentary Pharmacology and Therapeutics, 2019, 49, 1518-1527.	1.9	40
149	Efficacy and Safety of Ornithine Phenylacetate for Treating Overt Hepatic Encephalopathy in a Randomized Trial. Clinical Gastroenterology and Hepatology, 2021, 19, 2626-2635.e7.	2.4	40
150	Pathogenesis and diagnosis of hepatic encephalopathy. Expert Review of Gastroenterology and Hepatology, 2010, 4, 365-378.	1.4	39
151	Useful Tests for Hepatic Encephalopathy in Clinical Practice. Current Gastroenterology Reports, 2014, 16, 362.	1.1	39
152	Gut microbial RNA and DNA analysis predicts hospitalizations in cirrhosis. JCI Insight, 2018, 3, .	2.3	38
153	Fractional excretion of urea: A simple tool for the differential diagnosis of acute kidney injury in cirrhosis. Hepatology, 2018, 68, 224-233.	3.6	37
154	Liver transplantation significantly improves global functioning and cerebral processing. Liver Transplantation, 2016, 22, 1379-1390.	1.3	35
155	Gut microbial composition can differentially regulate bile acid synthesis in humanized mice. Hepatology Communications, 2017, 1, 61-70.	2.0	35
156	Deleterious Effect of Cirrhosis on Outcomes After Motor Vehicle Crashes Using the Nationwide Inpatient Sample. American Journal of Gastroenterology, 2008, 103, ???-???.	0.2	34
157	Gut Microbiota Modulation and Fecal Transplantation: An Overview on Innovative Strategies for Hepatic Encephalopathy Treatment. Journal of Clinical Medicine, 2021, 10, 330.	1.0	33
158	Impact of Antibiotic Resistance Genes in Gut Microbiome of Patients With Cirrhosis. Gastroenterology, 2021, 161, 508-521.e7.	0.6	33
159	Promises of microbiome-based therapies. Journal of Hepatology, 2022, 76, 1379-1391.	1.8	33
160	The irony of herbal hepatitis: Ma-Huang-induced hepatotoxicity associated with compound heterozygosity for hereditary hemochromatosis. Digestive Diseases and Sciences, 2003, 48, 1925-1928.	1.1	31
161	Predicting Hepatic Encephalopathy-Related Hospitalizations Using a Composite Assessment of Cognitive Impairment and Frailty in 355 Patients With Cirrhosis. American Journal of Gastroenterology, 2018, 113, 1506-1515.	0.2	31
162	Diet and cognition in chronic liver disease. Current Opinion in Gastroenterology, 2011, 27, 174-179.	1.0	30

#	ARTICLE	IF	CITATIONS
163	The Human Gut Microbiome in Liver Diseases. <i>Seminars in Liver Disease</i> , 2017, 37, 128-140.	1.8	30
164	Nutritional Assessment in Inpatients With Cirrhosis Can Be Improved After Training and Is Associated With Lower Readmissions. <i>Liver Transplantation</i> , 2019, 25, 1790-1799.	1.3	30
165	Effects of Alcohol on the Brain in Cirrhosis: Beyond Hepatic Encephalopathy. <i>Alcoholism: Clinical and Experimental Research</i> , 2018, 42, 660-667.	1.4	29
166	Telehealth-Based Evaluation Identifies Patients Who Are Not Candidates for Liver Transplantation. <i>Clinical Gastroenterology and Hepatology</i> , 2019, 17, 207-209.e1.	2.4	29
167	Cognitive Reserve Is a Determinant of Health-related Quality of Life in Patients With Cirrhosis, Independent of Covert Hepatic Encephalopathy and Model for End-Stage Liver Disease Score. <i>Clinical Gastroenterology and Hepatology</i> , 2015, 13, 987-991.	2.4	28
168	Altered Microbiota in Cirrhosis and Its Relationship to the Development of Infection. <i>Clinical Liver Disease</i> , 2019, 14, 107-111.	1.0	28
169	Diagnosis of covert hepatic encephalopathy: a multi-center study testing the utility of single versus combined testing. <i>Metabolic Brain Disease</i> , 2019, 34, 289-295.	1.4	28
170	Cognitive performance as a predictor of hepatic encephalopathy in pretransplant patients with cirrhosis receiving psychoactive medications: A prospective study. <i>Liver Transplantation</i> , 2012, 18, 1179-1187.	1.3	27
171	Modified-orientation log to assess hepatic encephalopathy. <i>Alimentary Pharmacology and Therapeutics</i> , 2012, 35, 913-920.	1.9	27
172	Mitochondrial oxysterol biosynthetic pathway gives evidence for CYP7B1 as controller of regulatory oxysterols. <i>Journal of Steroid Biochemistry and Molecular Biology</i> , 2019, 189, 36-47.	1.2	27
173	Variability and Lability of Ammonia Levels in Healthy Volunteers and Patients With Cirrhosis: Implications for Trial Design and Clinical Practice. <i>American Journal of Gastroenterology</i> , 2020, 115, 783-785.	0.2	27
174	Admission Urinary and Serum Metabolites Predict Renal Outcomes in Hospitalized Patients With Cirrhosis. <i>Hepatology</i> , 2021, 74, 2699-2713.	3.6	27
175	Covert Hepatic Encephalopathy. <i>Journal of Clinical Gastroenterology</i> , 2017, 51, 118-126.	1.1	26
176	Assessment of the spectrum of hepatic encephalopathy: A multicenter study. <i>Liver Transplantation</i> , 2018, 24, 587-594.	1.3	26
177	The Influence of the Microbiome on NAFLD and NASH. <i>Clinical Liver Disease</i> , 2021, 17, 15-18.	1.0	26
178	Cirrhosis Is Associated With High Mortality and Readmissions Over 90 Days Regardless of COVID-19: A Multicenter Cohort. <i>Liver Transplantation</i> , 2021, 27, 1343-1347.	1.3	25
179	Postoperative management of noniatrogenic traumatic bile duct injuries: role of endoscopic retrograde cholangiopancreatography. <i>Surgical Endoscopy and Other Interventional Techniques</i> , 2006, 20, 974-977.	1.3	24
180	New concepts on intestinal microbiota and the role of the non-absorbable antibiotics with special reference to rifaximin in digestive diseases. <i>Digestive and Liver Disease</i> , 2018, 50, 741-749.	0.4	24

#	ARTICLE	IF	CITATIONS
181	Muscle and Mortality in Cirrhosis. <i>Clinical Gastroenterology and Hepatology</i> , 2012, 10, 100-102.	2.4	23
182	Asymmetric dimethylarginine is strongly associated with cognitive dysfunction and brain MR spectroscopic abnormalities in cirrhosis. <i>Journal of Hepatology</i> , 2013, 58, 38-44.	1.8	23
183	In Patients With Cirrhosis, Driving Simulator Performance Is Associated With Real-life Driving. <i>Clinical Gastroenterology and Hepatology</i> , 2016, 14, 747-752.	2.4	23
184	Clinical science workshop: targeting the gut-liver-brain axis. <i>Metabolic Brain Disease</i> , 2016, 31, 1327-1337.	1.4	23
185	High-dose vitamin E supplementation does not diminish ribavirin-associated haemolysis in hepatitis C treatment with combination standard \pm -interferon and ribavirin. <i>Alimentary Pharmacology and Therapeutics</i> , 2004, 20, 1189-1193.	1.9	22
186	Utility of the EncephalApp Stroop Test for covert hepatic encephalopathy screening in Chinese cirrhotic patients. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2019, 34, 1843-1850.	1.4	22
187	Circulating microbiome in patients with portal hypertension. <i>Gut Microbes</i> , 2022, 14, 2029674.	4.3	22
188	The Relationship between Marital Status and Psychological Resilience in Chronic Pain. <i>Pain Research and Treatment</i> , 2013, 2013, 1-8.	1.7	21
189	MELD Score Does Not Discriminate Against Patients with Hepatic Encephalopathy. <i>Digestive Diseases and Sciences</i> , 2005, 50, 753-756.	1.1	20
190	Hepatic Encephalopathy Is Associated with Persistent Learning Impairments Despite Adequate Medical Treatment: A Multicenter, International Study. <i>Digestive Diseases and Sciences</i> , 2017, 62, 794-800.	1.1	20
191	Gender-Specific Differences in Baseline, Peak, and Delta Serum Creatinine: The NACSELD Experience. <i>Digestive Diseases and Sciences</i> , 2017, 62, 768-776.	1.1	19
192	Gut-liver axis alterations in alcoholic liver disease: Are bile acids the answer?. <i>Hepatology</i> , 2018, 67, 2074-2075.	3.6	19
193	Disruption of sleep architecture in minimal hepatic encephalopathy and ghrelin secretion. <i>Alimentary Pharmacology and Therapeutics</i> , 2011, 34, 103-105.	1.9	18
194	Variations in albumin use in patients with cirrhosis: An AASLD members survey. <i>Hepatology</i> , 2015, 62, 1923-1924.	3.6	18
195	In Silico Structure-Based Design of a Potent and Selective Small Peptide Inhibitor of Protein Tyrosine Phosphatase 1B, A Novel Therapeutic Target for Obesity and Type 2 Diabetes Mellitus: A Computer Modeling Approach. <i>Journal of Biomolecular Structure and Dynamics</i> , 2006, 23, 377-384.	2.0	17
196	Assessment of Minimal Hepatic Encephalopathy (with Emphasis on Computerized Psychometric Tests). <i>Clinics in Liver Disease</i> , 2012, 16, 43-55.	1.0	17
197	Outcomes in Patients With Cirrhosis on Primary Compared to Secondary Prophylaxis for Spontaneous Bacterial Peritonitis. <i>American Journal of Gastroenterology</i> , 2019, 114, 599-606.	0.2	17
198	Cognition and hospitalizations are linked with salivary and faecal microbiota in cirrhosis cohorts from the USA and Mexico. <i>Liver International</i> , 2020, 40, 1395-1407.	1.9	17

#	ARTICLE	IF	CITATIONS
199	Underutilization of Hospice in Inpatients with Cirrhosis: The NACSELD Experience. <i>Digestive Diseases and Sciences</i> , 2020, 65, 2571-2579.	1.1	17
200	Low Predictability of Readmissions and Death Using Machine Learning in Cirrhosis. <i>American Journal of Gastroenterology</i> , 2021, 116, 336-346.	0.2	17
201	Non-selective beta-blockers are not associated with serious infections in veterans with cirrhosis. <i>Alimentary Pharmacology and Therapeutics</i> , 2013, 38, 407-414.	1.9	16
202	Overt hepatic encephalopathy: development of a novel clinician reported outcome tool and electronic caregiver diary. <i>Metabolic Brain Disease</i> , 2016, 31, 1081-1093.	1.4	16
203	Hepatic encephalopathy: classification and treatment. <i>Journal of Hepatology</i> , 2018, 68, 838-839.	1.8	16
204	Distinct gut microbial compositional and functional changes associated with impaired inhibitory control in patients with cirrhosis. <i>Gut Microbes</i> , 2021, 13, 1953247.	4.3	16
205	High-Fat Diet Modulates Hepatic Amyloid β and Cerebrosterol Metabolism in the Triple Transgenic Mouse Model of Alzheimer's Disease. <i>Hepatology Communications</i> , 2021, 5, 446-460.	2.0	16
206	Overt hepatic encephalopathy impairs learning on the EncephalApp stroop which is reversible after liver transplantation. <i>Liver Transplantation</i> , 2017, 23, 1396-1403.	1.3	15
207	Alterations in Skin Microbiomes of Patients With Cirrhosis. <i>Clinical Gastroenterology and Hepatology</i> , 2019, 17, 2581-2591.e15.	2.4	15
208	Increased Risk of ACLF and Inpatient Mortality in Hospitalized Patients with Cirrhosis and Hepatic Hydrothorax. <i>Digestive Diseases and Sciences</i> , 2021, 66, 3612-3618.	1.1	15
209	Driving Simulation Can Improve Insight into Impaired Driving Skills in Cirrhosis. <i>Digestive Diseases and Sciences</i> , 2012, 57, 554-560.	1.1	14
210	Progression of Stage 2 and 3 Acute Kidney Injury in Patients With Decompensated Cirrhosis and Ascites. <i>Clinical Gastroenterology and Hepatology</i> , 2021, 19, 1661-1669.e2.	2.4	14
211	Getting to implementation: a protocol for a Hybrid III stepped wedge cluster randomized evaluation of using data-driven implementation strategies to improve cirrhosis care for Veterans. <i>Implementation Science</i> , 2020, 15, 92.	2.5	14
212	Gut Microbial Signature of Hepatocellular Cancer in Men With Cirrhosis. <i>Liver Transplantation</i> , 2021, 27, 629-640.	1.3	14
213	Failure to fully disclose during pretransplant psychological evaluation in alcoholic liver disease: A driving under the influence corroboration study. <i>Liver Transplantation</i> , 2008, 14, 1632-1636.	1.3	13
214	Effect of Obstructive Sleep Apnea on the Sleep Architecture in Cirrhosis. <i>Journal of Clinical Sleep Medicine</i> , 2013, 09, 247-251.	1.4	13
215	Serum and urinary metabolomics and outcomes in cirrhosis. <i>PLoS ONE</i> , 2019, 14, e0223061.	1.1	13
216	Metabolomics and microbial composition increase insight into the impact of dietary differences in cirrhosis. <i>Liver International</i> , 2020, 40, 416-427.	1.9	13

#	ARTICLE	IF	CITATIONS
217	Current and future diagnosis of hepatic encephalopathy. <i>Metabolic Brain Disease</i> , 2010, 25, 107-110.	1.4	12
218	What Is Driving the Legal Interest in Hepatic Encephalopathy?. <i>Clinical Gastroenterology and Hepatology</i> , 2011, 9, 97-98.	2.4	12
219	The Hepatic Innovation Team Collaborative: A Successful Population-Based Approach to Hepatocellular Carcinoma Surveillance. <i>Cancers</i> , 2021, 13, 2251.	1.7	12
220	Stool microbiota are superior to saliva in distinguishing cirrhosis and hepatic encephalopathy using machine learning. <i>Journal of Hepatology</i> , 2022, 76, 600-607.	1.8	12
221	Gut Microbiome and Alcohol-associated Liver Disease. <i>Journal of Clinical and Experimental Hepatology</i> , 2022, 12, 1349-1359.	0.4	12
222	Elevated liver enzymes following polytraumatic injury. <i>Journal of Rehabilitation Research and Development</i> , 2014, 51, 869-874.	1.6	11
223	Patient Acceptance of Lactulose Varies Between Indian and American Cohorts: Implications for Comparing and Designing Global Hepatic Encephalopathy Trials. <i>Journal of Clinical and Experimental Hepatology</i> , 2018, 8, 109-115.	0.4	11
224	Validation of a Simple Quality of Life Score for Identification of Minimal and Prediction of Overt Hepatic Encephalopathy. <i>Hepatology Communications</i> , 2020, 4, 1353-1361.	2.0	11
225	Progression to Cirrhosis Leads to Improvement in Atherogenic Milieu. <i>Digestive Diseases and Sciences</i> , 2021, 66, 263-272.	1.1	11
226	The Prediction of In-Hospital Mortality in Decompensated Cirrhosis with Acute-on-Chronic Liver Failure. <i>Liver Transplantation</i> , 2022, 28, 560-570.	1.3	11
227	QuickStroop, a Shortened Version of EncephalApp, Detects Covert Hepatic Encephalopathy With Similar Accuracy Within One Minute. <i>Clinical Gastroenterology and Hepatology</i> , 2023, 21, 136-142.	2.4	11
228	Core implementation strategies for improving cirrhosis care in the Veterans Health Administration. <i>Hepatology</i> , 2022, 76, 404-417.	3.6	11
229	Dosing of Rifaximin Soluble Solid Dispersion Tablets in Adults With Cirrhosis: 2 Randomized, Placebo-controlled Trials. <i>Clinical Gastroenterology and Hepatology</i> , 2023, 21, 723-731.e9.	2.4	11
230	Endoscopic Band Ligation of Esophageal Varices in Patients on Anticoagulation. <i>Journal of Clinical Gastroenterology</i> , 2008, 42, 782-785.	1.1	10
231	Symptom Domain Groups of the Patient-Reported Outcomes Measurement Information System Tools Independently Predict Hospitalizations and Re-hospitalizations in Cirrhosis. <i>Digestive Diseases and Sciences</i> , 2017, 62, 1173-1179.	1.1	10
232	Associations between Religiosity, Spirituality, and Happiness among Adults Living with Neurological Illness. <i>Geriatrics (Switzerland)</i> , 2018, 3, 35.	0.6	10
233	Sex is associated with differences in gut microbial composition and function in hepatic encephalopathy. <i>Journal of Hepatology</i> , 2021, 74, 80-88.	1.8	10
234	Hepatic Encephalopathy and Liver Transplantation: The Past, Present, and Future Toward Equitable Access. <i>Liver Transplantation</i> , 2021, 27, 1830-1843.	1.3	10

#	ARTICLE	IF	CITATIONS
235	Deprescribing medications that may increase the risk of hepatic encephalopathy: A qualitative study of patients with cirrhosis and their doctors. <i>United European Gastroenterology Journal</i> , 2021, 9, 193-202.	1.6	9
236	Fibrosisâ€ Predicts the Need for Mechanical Ventilation in a National Multiethnic Cohort of Corona Virus Disease 2019. <i>Hepatology Communications</i> , 2021, 5, 1605-1615.	2.0	9
237	Bristol Stool Scale as a Determinant of Hepatic Encephalopathy Management in Patients With Cirrhosis. <i>American Journal of Gastroenterology</i> , 2022, 117, 295-300.	0.2	9
238	Cirrhotic patients have good insight into their daily functional impairment despite prior hepatic encephalopathy: comparison with PROMIS norms. <i>Metabolic Brain Disease</i> , 2016, 31, 1199-1203.	1.4	8
239	No Association Between Quick Sequential Organ Failure Assessment and Outcomes of Patients With Cirrhosis and Infections. <i>Clinical Gastroenterology and Hepatology</i> , 2017, 15, 1803-1804.	2.4	8
240	Liver-Unrelated Comorbid Conditions Do Not Affect Cognitive Performance or Hepatic Encephalopathy Progression in Cirrhosis. <i>American Journal of Gastroenterology</i> , 2021, 116, 2385-2389.	0.2	8
241	Acuteâ€Chronic Liver Failure and Liver Transplantation: Putting the Cart Before the Horse in Data Analyses and Advocating for Model for Endâ€Stage Liver Disease Exceptions. <i>Liver Transplantation</i> , 2022, 28, 535-538.	1.3	8
242	Should a radiological diagnosis of hepatocellular carcinoma be routinely confirmed by a biopsy? NO. <i>European Journal of Internal Medicine</i> , 2012, 23, 37-39.	1.0	7
243	Tired of Hepatitis B?. <i>Digestive Diseases and Sciences</i> , 2016, 61, 953-954.	1.1	7
244	Adventures in Developing an App for Covert Hepatic Encephalopathy. <i>Clinical and Translational Gastroenterology</i> , 2017, 8, e85.	1.3	7
245	Brain Integrity Changes Underlying Cognitive and Functional Recovery Postliver Transplant Continue to Evolve Over 1 Year. <i>Transplantation</i> , 2018, 102, 461-470.	0.5	7
246	Gut Microbiota as Biosensors in Patients With Cirrhosis. <i>Cellular and Molecular Gastroenterology and Hepatology</i> , 2019, 8, 231-233.	2.3	7
247	Manipulation of the Gut-Liver Axis Using Microbiome Restoration Therapy in Primary Sclerosing Cholangitis. <i>American Journal of Gastroenterology</i> , 2019, 114, 1027-1029.	0.2	7
248	Effect of Increasing Age on Brain Dysfunction in Cirrhosis. <i>Hepatology Communications</i> , 2019, 3, 63-73.	2.0	7
249	Training of hepatology providers improves the screening and resultant interventions for alcohol use disorder. <i>Liver International</i> , 2020, 40, 2090-2094.	1.9	7
250	What Role Should Acuteâ€Chronic Liver Failure Play in Liver Transplant Prioritization? A Survey of USâ€Based Transplant Providers. <i>Liver Transplantation</i> , 2020, 26, 1658-1661.	1.3	7
251	What Diet Should I Recommend My Patient with Hepatic Encephalopathy?. <i>Current Hepatology Reports</i> , 2020, 19, 13-22.	0.4	7
252	Insurance Status But Not Race and Ethnicity Are Associated With Outcomes in a Large Hospitalized Cohort of Patients With Cirrhosis. <i>Clinical Gastroenterology and Hepatology</i> , 2021, 19, 565-572.e5.	2.4	7

#	ARTICLE	IF	CITATIONS
253	Interaction of Microbiome, Diet, and Hospitalizations Between Brazilian and American Patients With Cirrhosis. <i>Clinical Gastroenterology and Hepatology</i> , 2022, 20, 930-940.	2.4	7
254	Bowel Movement Frequency Is Not Linked With Cognitive Function in Cirrhosis. <i>Clinical Gastroenterology and Hepatology</i> , 2022, 20, e897-e901.	2.4	7
255	Hepatic Branch Vagotomy Modulates the Gut-Liver-Brain Axis in Murine Cirrhosis. <i>Frontiers in Physiology</i> , 2021, 12, 702646.	1.3	7
256	Bile Acids, Gut Microbiome and the Road to Fatty Liver Disease. , 2021, 12, 2719-2730.		7
257	Admission Serum Metabolites and Thyroxine Predict Advanced Hepatic Encephalopathy in a Multicenter Inpatient Cirrhosis Cohort. <i>Clinical Gastroenterology and Hepatology</i> , 2023, 21, 1031-1040.e3.	2.4	7
258	Impact of bacterial infections and spontaneous bacterial peritonitis prophylaxis on phage-bacterial dynamics in cirrhosis. <i>Hepatology</i> , 2022, 76, 1723-1734.	3.6	7
259	Natural History of Alcohol-Associated Liver Disease: Understanding the Changing Landscape of Pathophysiology and Patient Care. <i>Gastroenterology</i> , 2022, 163, 840-851.	0.6	7
260	Commentary: <scp>PPI</scp>s and risk of serious infection in decompensated cirrhosis – authors' reply. <i>Alimentary Pharmacology and Therapeutics</i> , 2012, 36, 1095-1095.	1.9	6
261	Effect of Post-Traumatic Stress Disorder on Cognitive Function and Covert Hepatic Encephalopathy Diagnosis in Cirrhotic Veterans. <i>Digestive Diseases and Sciences</i> , 2018, 63, 481-485.	1.1	6
262	Focused Education Increases Hepatocellular Cancer Screening in Patients with Cirrhosis Regardless of Functional Health Literacy. <i>Digestive Diseases and Sciences</i> , 2021, 66, 2603-2609.	1.1	6
263	Microbiome. <i>Clinics in Liver Disease</i> , 2020, 24, 493-520.	1.0	6
264	Cognitive Function in Liver Transplantation. <i>Current Transplantation Reports</i> , 2020, 7, 31-37.	0.9	6
265	Increased access to liver transplantation for patients with acute on chronic liver failure after implementation of Share 35 Rule: An analysis from the UNOS database. <i>Annals of Hepatology</i> , 2021, 23, 100288.	0.6	6
266	Pharmacokinetics/pharmacodynamics of L-ornithine phenylacetate in overt hepatic encephalopathy and the effect of plasma ammonia concentration reduction on clinical outcomes. <i>Clinical and Translational Science</i> , 2022, 15, 1449-1459.	1.5	6
267	Cognitive improvement after HCV eradication: Extending the benefits. <i>Hepatology</i> , 2013, 58, 480-482.	3.6	5
268	What Is the ethical (Not Legal) responsibility of a physician to treat minimal hepatic encephalopathy and advise patients not to drive?. <i>Clinical Liver Disease</i> , 2015, 6, 86-89.	1.0	5
269	Letter to the Editor: Defining Acute on Chronic Liver Failure: More Elusive Than Ever. <i>Hepatology</i> , 2019, 70, 450-451.	3.6	5
270	Hospitalized Women With Cirrhosis Have More Nonhepatic Comorbidities and Associated Complications Than Men. <i>Clinical Gastroenterology and Hepatology</i> , 2020, 18, 3046-3048.	2.4	5

#	ARTICLE	IF	CITATIONS
271	Cost-effectiveness of integrating gut microbiota analysis into hospitalisation prediction in cirrhosis. <i>GastroHep</i> , 2020, 2, 79-86.	0.3	5
272	Perspectives of Inpatients With Cirrhosis and Caregivers on Using Health Information Technology: Cross-sectional Multicenter Study. <i>Journal of Medical Internet Research</i> , 2021, 23, e24639.	2.1	5
273	Multiple bacterial virulence factors focused on adherence and biofilm formation associate with outcomes in cirrhosis. <i>Gut Microbes</i> , 2021, 13, 1993584.	4.3	5
274	Patient and provider level factors that underlie alcohol use disorder treatment offer and acceptance in veterans with cirrhosis. <i>Alcoholism: Clinical and Experimental Research</i> , 2022, 46, 809-814.	1.4	5
275	Development of New Mental and Physical Health Sequelae among US Veterans after COVID-19. <i>Journal of Clinical Medicine</i> , 2022, 11, 3390.	1.0	5
276	Pretreatment Laparoscopic Appearance of the Liver can Predict Response to Combination Therapy with Interferon Alpha 2B and Ribavirin in Chronic Hepatitis C. <i>Gastrointestinal Endoscopy</i> , 2003, 58, 380-383.	0.5	4
277	Esophageal Veggie Spasms: A Food-Specific Cause of Chest Distress. <i>American Journal of Gastroenterology</i> , 2004, 99, 1396-1398.	0.2	4
278	Another indication for transnasal, unsedated upper-GI endoscopy. <i>Gastrointestinal Endoscopy</i> , 2005, 62, 667-668.	0.5	4
279	The role of endoscopy in noniatrogenic injuries of the liver. <i>Current Gastroenterology Reports</i> , 2007, 9, 147-150.	1.1	4
280	Shared Symptoms and Putative Biological Mechanisms in Chronic Liver Disease. <i>Biological Research for Nursing</i> , 2015, 17, 222-229.	1.0	4
281	Does the death of a spouse increase subjective well-being: An assessment in a population of adults with neurological illness. <i>Healthy Aging Research</i> , 2016, 5, 1-9.	0.3	4
282	Hepatic encephalopathy and traffic accidents: Vigilance is needed!. <i>Journal of Hepatology</i> , 2019, 70, 590-592.	1.8	4
283	Fecal microbial transplant reduces short-term cravings, improves quality of life and microbial diversity in cirrhosis and alcohol use disorder: a randomized, placebo-controlled, clinical trial. <i>Journal of Hepatology</i> , 2020, 73, S59-S60.	1.8	4
284	Stool microbiota show greater linkages with plasma metabolites compared to salivary microbiota in a multinational cirrhosis cohort. <i>Liver International</i> , 2022, 42, 2274-2282.	1.9	4
285	Safety and feasibility of evaluating airway-protective reflexes during sleep: new technique and preliminary results. <i>Gastrointestinal Endoscopy</i> , 2007, 65, 483-486.	0.5	3
286	Methanogenesis in Irritable Bowel Syndrome: A Lot of Hot Air?. <i>Digestive Diseases and Sciences</i> , 2012, 57, 3045-3046.	1.1	3
287	Microbiome and complications of liver disease. <i>Clinical Liver Disease</i> , 2015, 5, 96-99.	1.0	3
288	The brain gets its say: Hepatic encephalopathy and its evolving role in transplant priority. <i>Liver Transplantation</i> , 2016, 22, 1319-1320.	1.3	3

#	ARTICLE	IF	CITATIONS
289	Grading the range of hepatic encephalopathy from overt to covert: Animals to the rescue!. <i>Hepatology</i> , 2017, 66, 10-12.	3.6	3
290	SAT-014-Efficacy of rifaximin soluble solid dispersion in patients with early decompensated cirrhosis and a Conn score of 0: A post hoc analysis of a randomized, double-blind, placebo-controlled trial. <i>Journal of Hepatology</i> , 2019, 70, e631.	1.8	3
291	Characterizing patient-reported outcomes in veterans with cirrhosis. <i>PLoS ONE</i> , 2020, 15, e0238712.	1.1	3
292	MELD 3.0: One Small Step for Womankind or One Big Step for Everyone?. <i>Gastroenterology</i> , 2022, 162, 1780-1781.	0.6	3
293	Antibiotic Prophylaxis in Acute Liver Failure: Friend or Foe?. <i>Clinical Gastroenterology and Hepatology</i> , 2014, 12, 1950-1952.	2.4	2
294	Editorial: should the inappropriate use of proton pump inhibitors be a quality assurance issue in cirrhotic patients?. <i>Alimentary Pharmacology and Therapeutics</i> , 2017, 45, 476-477.	1.9	2
295	Introduction and setting the scene: New nomenclature of hepatic encephalopathy and American Association for the Study of Liver Diseases/European Association for the Study of the Liver guidelines. <i>Clinical Liver Disease</i> , 2017, 9, 48-51.	1.0	2
296	Reply. <i>Hepatology</i> , 2018, 68, 1206-1206.	3.6	2
297	Acute-on-Chronic Liver Failure Prognosis Using North American Consortium for the Study of End-Stage Liver Disease's Acute-on-Chronic Liver Failure Score: Paving the Road to Transplant?. <i>Liver Transplantation</i> , 2020, 26, 179-181.	1.3	2
298	Transmitting Diet-Related Microbial Benefit through Fecal Microbiota Transplant in NASH: Can Microbiota Cut Through the Fat?. <i>Hepatology Communications</i> , 2020, 4, 1559-1561.	2.0	2
299	Is There Evidence of the Hawthorne Effect in Quality Improvement of Nutritional Consultation in Inpatients With Cirrhosis?. <i>Liver Transplantation</i> , 2020, 26, 1049-1051.	1.3	2
300	Reply to: "You know my name, but not my story" Deciding on an accurate nomenclature for faecal microbiota transplantation. <i>Journal of Hepatology</i> , 2020, 72, 1213-1214.	1.8	2
301	Liver Transplant Is Associated with Sustained Improvement in Tandem Gait and Risk of Falls. <i>Digestive Diseases and Sciences</i> , 2021, 66, 1360-1366.	1.1	2
302	Is it time to spit? More evidence for the oral-gut-liver axis in liver disease. <i>Hepatology International</i> , 2021, 15, 4-5.	1.9	2
303	Prognosis of hospitalized patients with cirrhosis and acute kidney disease. <i>Liver International</i> , 2022, , .	1.9	2
304	Fecal transplant to mitigate hyperammonemia and hepatic encephalopathy in animal models. <i>Annals of Hepatology</i> , 2015, 14, 762-3.	0.6	2
305	Acute-on-Chronic Liver Failure. <i>American Journal of Gastroenterology</i> , 2022, 117, 831-834.	0.2	2
306	Area Deprivation Index and Gut-Brain Axis in Cirrhosis. <i>Clinical and Translational Gastroenterology</i> , 2022, 13, e00495.	1.3	2

#	ARTICLE	IF	CITATIONS
307	Substance use simulation impairs driving capability in patients with cirrhosis regardless of hepatic encephalopathy. <i>Hepatology Communications</i> , 2022, 6, 2867-2875.	2.0	2
308	Reply to Parikh and Butt. <i>American Journal of Gastroenterology</i> , 2012, 107, 486-487.	0.2	1
309	Commentary: <scp>TIPSS</scp> for Budd-Chiari syndrome. <i>Alimentary Pharmacology and Therapeutics</i> , 2014, 39, 1237-1238.	1.9	1
310	Commentary: probing probiotics in cirrhosis – a template for future studies? Author's reply. <i>Alimentary Pharmacology and Therapeutics</i> , 2014, 39, 1335-1336.	1.9	1
311	Liver capsule: Hepatic encephalopathy. <i>Hepatology</i> , 2015, 62, 955-955.	3.6	1
312	Covert and Overt Hepatic Encephalopathy: Current Options for Diagnosis and Treatment. <i>Current Hepatology Reports</i> , 2015, 14, 234-242.	0.4	1
313	Editorial: patient-reported outcomes in chronic <scp>HCV</scp> – a <scp>PROMIS</scp>ing approach to an ongoing problem. <i>Alimentary Pharmacology and Therapeutics</i> , 2018, 47, 1319-1320.	1.9	1
314	Tu1512 - Proton Pump Inhibitor Initiation and Withdrawal can Modulate Gut Microbiota in Patients with Decompensated Cirrhosis. <i>Gastroenterology</i> , 2018, 154, S-948-S-949.	0.6	1
315	SAT-139-Predictive factors for the development of acute-on-chronic liver failure in a North American cohort of hospitalized patients with cirrhosis and decompensation. <i>Journal of Hepatology</i> , 2019, 70, e691-e692.	1.8	1
316	PS-087-Fecal microbiota capsules are safe and effective in patients with recurrent hepatic encephalopathy: A randomized, blinded, placebo-controlled trial. <i>Journal of Hepatology</i> , 2019, 70, e55.	1.8	1
317	Microbiome metabolic therapies reduce microbiota-associated ammonia in ex vivo fecal samples from healthy subjects and patients with minimal hepatic encephalopathy and demonstrate improved tolerability over lactulose in a clinical study. <i>Journal of Hepatology</i> , 2020, 73, S721-S722.	1.8	1
318	Periodontitis is associated with increased liver fibrosis in a population-based cohort of US adults. <i>GastroHep</i> , 2021, 3, 179-184.	0.3	1
319	The Relationship Between the Gut Microbiota and Liver Disease. <i>Gastroenterology and Hepatology</i> , 2015, 11, 626-8.	0.2	1
320	Diagnosis and Treatment of Hepatic Encephalopathy. <i>Gastroenterology and Hepatology</i> , 2019, 15, 434-436.	0.2	1
321	Microbial Therapeutics in Liver Disease. , 2022, , 271-285.		1
322	Conformational basis of the receptor-binding potency of normal and mutant insulin molecules with relevance to the pathophysiology of noninsulin dependent diabetes mellitus (NIDDM). <i>International Journal of Quantum Chemistry</i> , 1988, 34, 95-101.	1.0	0
323	Commentary: non-haemodynamic effects of beta-blockers in cirrhosis - more than meets the eye? Authors' reply. <i>Alimentary Pharmacology and Therapeutics</i> , 2013, 38, 653-653.	1.9	0
324	Reply. <i>Clinical Gastroenterology and Hepatology</i> , 2015, 13, 2028.	2.4	0

#	ARTICLE	IF	CITATIONS
325	Neurological examination. <i>Clinical Liver Disease</i> , 2016, 7, 151-153.	1.0	0
326	Reply. <i>Hepatology</i> , 2017, 66, 1355-1356.	3.6	0
327	Reply. <i>Hepatology</i> , 2018, 68, 791-791.	3.6	0
328	Comment: Rifampin-Resistant <i>Staphylococcus aureus</i> Bacteremia in a Patient on Chronic Rifaximin. <i>Annals of Pharmacotherapy</i> , 2018, 52, 94-95.	0.9	0
329	Concise Commentary: Remaining Outside the Hospital Is a Golden State in Cirrhosis—Lessons from California. <i>Digestive Diseases and Sciences</i> , 2018, 63, 2275-2276.	1.1	0
330	Reply. <i>Hepatology</i> , 2018, 68, 2046-2048.	3.6	0
331	Definition and Changes in Nomenclature of Hepatic Encephalopathy. , 2018, , 1-13.		0
332	Reply. <i>Liver Transplantation</i> , 2019, 25, 1586-1587.	1.3	0
333	Reply. <i>Gastroenterology</i> , 2019, 157, 902-903.	0.6	0
334	The Toll of Hyperammonemia on the Brain. <i>Cellular and Molecular Gastroenterology and Hepatology</i> , 2019, 8, 649-650.	2.3	0
335	SAT-013-Potentially Preventable readmissions and complications in hospitalized patients with hepatic encephalopathy in a large multi-center cohort. <i>Journal of Hepatology</i> , 2019, 70, e630-e631.	1.8	0
336	Altered gut-liver axis in liver diseases. <i>Liver Research</i> , 2019, 3, 1-2.	0.5	0
337	Stage 1b acute kidney injury in cirrhosis is likely due to underlying chronic kidney disease and would be more appropriately re-classified as acute-on-chronic kidney disease. <i>Journal of Hepatology</i> , 2020, 73, S35-S36.	1.8	0
338	Gut virome changes with disease progression in patients with cirrhosis and is inversely related to the bacterial metagenome. <i>Journal of Hepatology</i> , 2020, 73, S81-S82.	1.8	0
339	Multi-modal training of specialty clinical trainees improves the detection and subsequent interventions for alcohol use disorder. <i>Journal of Hepatology</i> , 2020, 73, S179-S180.	1.8	0
340	Gut microbiota are associated with minimal hepatic encephalopathy (MHE) in cirrhosis regardless of country of origin. <i>Journal of Hepatology</i> , 2020, 73, S237-S238.	1.8	0
341	Safety, tolerability, pharmacokinetics and pharmacodynamic activity of terlipressin delivered by continuous intravenous infusion in patients with cirrhosis and refractory ascites: a phase 2a open-label trial. <i>Journal of Hepatology</i> , 2020, 73, S718-S719.	1.8	0
342	Validation of encephalapp stroop for minimal hepatic encephalopathy diagnosis in elderly patients with cirrhosis: a multi-center study. <i>Journal of Hepatology</i> , 2020, 73, S719-S721.	1.8	0

#	ARTICLE	IF	CITATIONS
343	Reply. Clinical Gastroenterology and Hepatology, 2021, , .	2.4	0
344	REPLY:. Hepatology, 2021, 74, 2916-2917.	3.6	0
345	Infections in Critically Ill Cirrhosis Patients. , 2020, , 105-122.		0